Clear Eyes Eye Drops Recall, What the 2025 Recall Means for Users

Quick Answer

The FDA announced a recall of Clear Eyes Maximum Itchy Eye Relief on July 29, 2026, after the product's distributor, Prestige Consumer Healthcare, cited a "lack of assurance of sterility." The recall covers nearly 40,000 bottles from a single production lot, identified by Lot 2552A with an expiration date of September 30, 2027. The recall was upgraded to a Class II classification on August 14, 2026, meaning potential health effects are temporary or reversible, with serious harm considered unlikely.

Key Facts

• Product recalled: Clear Eyes Maximum Itchy Eye Relief (NDC: 67172-999-01, UPC: 6 78112 65920 3)
• Quantity affected: 39,060 bottles in 15-milliliter (0.5-ounce) packaging
• Lot identification: Lot 2552A, Exp. 09/30/2027
• Recall initiation date: July 29, 2026
• Classification update: Class II on August 14, 2026
• Reason for recall: Lack of assurance of sterility; potential contamination
• Recalling company: Prestige Consumer Healthcare (also referenced as Prestige Brands Holdings), a New York-based company
• Recall number: D-0766-2026
• Distribution: Nationwide, including CVS, Walgreens, Amazon, Walmart, Dollar General, and Target
• Consumer action: Return product to place of purchase for a refund; do not use affected bottles

---

What Led to the Recall

The recall of Clear Eyes Maximum Itchy Eye Relief did not happen in isolation. It follows a pattern of increasing scrutiny on ophthalmic products over the past several years.

The FDA's involvement began in late July 2026 when Prestige Consumer Healthcare voluntarily initiated a recall based on concerns about sterility assurance. The key detail here is the phrase "lack of assurance of sterility." This is not the same as confirming active contamination.

The FDA has stated that the product is not actively contaminated, according to reporting from Ophthalmology Times. Rather, the manufacturer could not provide sufficient evidence that the product met sterility standards throughout its shelf life.

This distinction matters because it affects how consumers should interpret the risk. Sterility assurance in eye drops is not a minor technicality.

The eye is a delicate organ, and the cornea can be vulnerable to microbial keratitis, a serious infection that can cause pain, vision changes, and in severe cases, permanent damage. Because eye drops bypass many of the body's natural defenses, any uncertainty about sterility warrants caution.

This is why regulators treat sterility issues in ophthalmic products with particular seriousness. The FDA initially announced the recall on July 29, 2026.

On August 14, 2026, the agency updated the classification to Class II. Under FDA definitions, a Class II recall involves a situation where use of the product may cause temporary or medically reversible adverse health consequences, with the probability of serious harm being remote.

This classification is a formal acknowledgment that while the risk is not catastrophic, it is real enough to warrant public notification and product removal. The timing of the recall upgrade is worth noting.

The initial announcement and the classification update were roughly two weeks apart. This gap is typical as the FDA reviews the manufacturer's data and determines the appropriate risk category.

The upgrade to Class II also gives consumers a clearer picture of what the agency actually believes the risk level to be. For context, this recall is part of a broader trend.

Eye drop recalls have occurred repeatedly in recent years. In February 2023, Artificial Tears Lubricant Eye Drops manufactured by Global Pharma Healthcare were recalled over potential contamination.

That recall was particularly serious because it was linked to bacterial infections. In May 2025, artificial tears made by BRS Analytical Service and distributed by AvKARE were recalled, along with lubricant eye ointments from Allergan due to tube sealing issues.

In September 2024, lubricant eye ointments from Brassica Pharma were pulled due to sterility concerns identified during an FDA facility inspection. More recently, in July 2026, Lupin Pharmaceuticals recalled 2.5 million bottles of prednisoLONE Acetate Ophthalmic Suspension, a prescription eye drop.

The Clear Eyes recall shares a common thread with these other events: the fundamental challenge of maintaining sterility in liquid products packaged for multi-dose use. Multi-dose eye drops contain preservatives designed to prevent microbial growth after the bottle is opened, but the manufacturing process itself must ensure the product is sterile before it reaches consumers.

When that assurance breaks down, even without confirmed contamination, the FDA treats it as a reportable event.

The Key Players Involved

Understanding who is responsible for what in this recall helps clarify the chain of accountability. Prestige Consumer Healthcare is the company that distributes Clear Eyes products.

The company initiated the recall voluntarily, which is important. Voluntary recalls are typically viewed as the responsible course of action when a manufacturer identifies a potential quality issue.

The company did not wait for the FDA to force the issue, and it moved quickly to inform the public and retailers. The company is described as New York-based in CBS News reporting, while other sources refer to Prestige Brands Holdings, which appears to be the parent entity.

The company distributes the eye drops to major retail outlets across the country, including pharmacies like CVS and Walgreens, big-box stores like Walmart and Target, dollar stores like Dollar General, and online retailers like Amazon. The FDA plays the regulatory role in this recall.

The agency issued the initial recall notice, tracked the scope of the affected product, and later upgraded the classification to Class II. The FDA does not manufacture the product or control the supply chain, but it is the authority that monitors compliance and communicates risk to the public.

Retailers are the final link in the chain. Because the product is over-the-counter, consumers encounter it on store shelves rather than through a prescription.

This means retailers have a responsibility to remove affected bottles from their inventory and to process returns for customers who already purchased the product. The recall number D-0766-2026 and the specific lot code 2552A give regulators and consumers precise identifiers.

The lot code is crucial because it allows consumers to determine whether the specific bottle they own is part of the recall. Not all Clear Eyes products are affected, and even among Maximum Itchy Eye Relief bottles, only those from this specific lot are included.

One notable aspect of this recall is the relatively contained scope. Nearly 40,000 bottles is not a small number, but it is far less than some other eye drop recalls.

The Lupin recall in July 2026, for example, involved 2.5 million bottles. The Clear Eyes recall is limited to a single production lot, which suggests the issue may be isolated to a specific manufacturing run rather than a systemic problem across the entire product line.

What the Class II Classification Actually Means

The FDA's recall classification system can be confusing for consumers. It is not a measure of how widespread a recall is, but rather an assessment of the potential health consequences.

Class I recalls involve situations where there is a reasonable probability that use of the product will cause serious adverse health consequences or death. These are the most severe.

Class II recalls involve situations where use of the product may cause temporary or medically reversible adverse health consequences, with the probability of serious harm being remote. Class III recalls involve situations where use of the product is not likely to cause adverse health consequences.

The Clear Eyes recall was classified as Class II. According to reporting from Ophthalmology Times, the FDA indicated that temporary or reversible health effects are possible, but serious harm is unlikely.

This is reassuring in one sense: the agency does not believe this product poses a severe public health threat. But it is also a reminder that "unlikely" is not "impossible."

What kind of health effects could occur?

If a contaminated product were used, the most common concerns would be eye irritation, redness, discharge, or infection. In the context of an itchy eye relief product, some of these symptoms might be mistaken for the original condition the drops were meant to treat.

This is why the FDA and the manufacturer are urging consumers to stop using the product even if they have not noticed any problems. The classification also has implications for the manufacturer.

A Class II recall is less damaging to a company's reputation than a Class I, but it still represents a significant quality control failure. The company will need to investigate the root cause of the sterility issue, implement corrective actions, and work with the FDA to ensure the problem does not recur.

It is worth emphasizing that the FDA has stated the product is not actively contaminated. The issue is a lack of assurance, not confirmed contamination.

This is a meaningful distinction. In some past recalls, such as the 2023 Artificial Tears recall, there were confirmed cases of bacterial infection linked to the product.

In this case, the available information does not indicate that any infections have been confirmed or that any illnesses have been reported. However, the absence of confirmed harm does not mean the recall is unnecessary.

The entire point of sterility assurance is to prevent harm before it occurs. If a manufacturer cannot prove that a product is sterile, the prudent course is to remove it from the market.

This is the approach Prestige Consumer Healthcare took, and it aligns with how the FDA expects responsible manufacturers to behave.

How to Check if Your Bottle Is Affected

The most practical question for consumers is whether their specific bottle is part of the recall. The answer requires checking two pieces of information printed on the packaging: the lot number and the expiration date.

The affected product is Clear Eyes Maximum Itchy Eye Relief in 15-milliliter bottles. The lot number is 2552A, and the expiration date is September 30, 2027.

Both must match for the bottle to be included in the recall. A bottle with a different lot number or a different expiration date is not part of this specific recall.

Consumers should also verify the product name. The recall applies specifically to Clear Eyes Maximum Itchy Eye Relief.

Other Clear Eyes products, such as those for redness relief or dry eye, are not mentioned in the recall documentation. The NDC code for the affected product is 67172-999-01, and the UPC is 6 78112 65920 3.

These codes can be used to confirm the exact product if there is any confusion about the name. If a consumer has an affected bottle, the recommended action is straightforward: do not use the drops, and return them to the store where they were purchased for a refund.

The recall has been active since July 29, 2026, and was still ongoing as of late August 2026, according to NBC News reporting. For consumers who have already used the product, there is no indication in the available information that they need to seek medical attention absent symptoms.

If any irritation, discomfort, or unusual symptoms develop, consulting a healthcare provider is a reasonable precaution. Otherwise, the primary action is to discontinue use and process the return.

The recall applies to products sold nationwide. The distribution network includes major pharmacy chains, discount retailers, grocery stores, and online marketplaces.

Because the product is over-the-counter, consumers could have purchased it in many different settings. The return process should be consistent across retailers, though policies may vary slightly by store.

Why Eye Drop Sterility Matters

The attention on this recall is not an overreaction. Eye drops occupy a unique position in the world of consumer health products.

They are applied directly to the surface of the eye, an area with limited natural protection against microbial invasion. Unlike a product applied to the skin, where the body has multiple layers of defense, the eye relies primarily on tears and the blink reflex to clear contaminants.

When eye drops are not sterile, the risks include microbial keratitis, an infection of the cornea that can cause pain, blurred vision, sensitivity to light, and in severe cases, scarring or vision loss. Bacterial infections of the eye can progress rapidly and may require intensive treatment.

Some infections are resistant to common antibiotics, which complicates treatment. The preservatives in multi-dose eye drops are designed to inhibit microbial growth once the bottle is opened.

But preservatives cannot compensate for a product that was not sterile at the time of manufacture. If the manufacturing process fails to eliminate microbes, the product can introduce contamination directly to the eye, bypassing the preservative system entirely.

This is why the FDA treats sterility assurance as a critical quality attribute for ophthalmic products. A manufacturer must not only produce sterile products, but must also be able to demonstrate that sterility was achieved and maintained.

When a manufacturer cannot provide this assurance, the FDA's expectation is that the product should not remain on the market. The pattern of eye drop recalls in recent years suggests that this is an area of ongoing concern.

The 2023 Artificial Tears recall was linked to a rare drug-resistant bacteria and resulted in serious infections and at least one reported death. That event raised awareness of the risks associated with non-sterile eye drops and prompted increased regulatory scrutiny.

Subsequent recalls, including the Clear Eyes recall, reflect a regulatory environment that is more attentive to potential issues in ophthalmic products. For consumers, the practical takeaway is that eye drops should be treated as medical products, not casual purchases.

Checking recall notices, verifying lot numbers, and paying attention to storage instructions are all reasonable habits. When a recall is announced, responding promptly is the safest course of action.

Frequently Asked Questions

How do I know if my Clear Eyes eye drops are part of the recall?

Check the box for the lot number and expiration date. If the lot reads 2552A and the expiration date reads September 30, 2027, the product is included in the recall.

The product must be Clear Eyes Maximum Itchy Eye Relief in a 15-milliliter bottle. Bottles with different lot numbers or expiration dates are not part of this recall.

What should I do with the recalled eye drops?

Do not use the product. Return the bottle to the store where it was purchased for a refund.

The recall applies to products sold at retailers including CVS, Walgreens, Amazon, Walmart, Dollar General, and Target. If returning to the store is not possible, contact the manufacturer for guidance.

Was anyone harmed by these eye drops?

The available information indicates that the recall was initiated due to a lack of assurance of sterility, and the FDA has stated the product is not actively contaminated. The recall was classified as Class II, meaning temporary or reversible health effects are possible but serious harm is unlikely.

No confirmed illnesses have been reported in the reference materials.

Why was the recall classified as Class II instead of Class I?

The FDA classification system assesses the potential for harm. Class I is reserved for situations where serious adverse health consequences or death are reasonably possible.

Class II applies when health effects are temporary or medically reversible and serious harm is remote. The FDA determined that this recall fits the Class II definition based on the available information.

Are other Clear Eyes products affected by this recall?

The recall applies specifically to Clear Eyes Maximum Itchy Eye Relief in lot 2552A with expiration date September 30, 2027. Other Clear Eyes products are not mentioned in the recall documentation.

Consumers should verify the product name, lot number, and expiration date before determining whether their bottle is affected.

Reference Notes

Information in this article is based on publicly available sources. Some details may change over time.

Verify with official sources before acting. The recall was ongoing as of August 22, 2026, and consumers should check the FDA website or contact Prestige Consumer Healthcare for the most current information.